Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy A Yap

Showing results (191-200 of 260) with videos related to

Pageof 26
Sort By:
NPJ Precision Oncology|July 15, 2023
Actionability classification of variants of unknown significance correlates with functional effectAmber Johnson, Patrick Kwok-Shing Ng, Michael Kahle, et al.
Investigational New Drugs|February 20, 2025
Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single-center, multi-arm phase Ib studyKyaw Z Thein, Daniel D Karp, Apostolia Tsimberidou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2011
Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignanciesDavid Olmos, Douglas Barker, Rohini Sharma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2018
Precision Oncology Decision Support: Current Approaches and Strategies for the FutureKatherine C Kurnit, Ecaterina E Ileana Dumbrava, Beate Litzenburger, et al.
Cancer Cell|March 14, 2018
BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination DeficiencyChaoyang Sun, Jun Yin, Yong Fang, et al.
Nature Medicine|January 13, 2026
Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trialTimothy A Yap, Randy F Sweis, Ulka Vaishampayan, et al.
Investigational New Drugs|November 3, 2021
Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single‑center, multi‑arm phase Ib studyKyaw Z Thein, Daniel D Karp, Apostolia Tsimberidou, et al.
Clinical Pharmacology and Therapeutics|August 21, 2025
Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor TuvusertibJatinder Kaur Mukker, Paul Matthias Diderichsen, Farina Hellmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2011
Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studiesTimothy A Yap, David Olmos, Andre T Brunetto, et al.
NPJ Precision Oncology|April 18, 2023
Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignanciesOmar Alhalabi, Roman Groisberg, Ralph Zinner, et al.
Pageof 26

Showing results (191-200 of 260) with videos related to

Sort By:
Pageof 26
NPJ Precision Oncology|July 15, 2023
Actionability classification of variants of unknown significance correlates with functional effectAmber Johnson, Patrick Kwok-Shing Ng, Michael Kahle, et al.
Investigational New Drugs|February 20, 2025
Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single-center, multi-arm phase Ib studyKyaw Z Thein, Daniel D Karp, Apostolia Tsimberidou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2011
Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignanciesDavid Olmos, Douglas Barker, Rohini Sharma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2018
Precision Oncology Decision Support: Current Approaches and Strategies for the FutureKatherine C Kurnit, Ecaterina E Ileana Dumbrava, Beate Litzenburger, et al.
Cancer Cell|March 14, 2018
BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination DeficiencyChaoyang Sun, Jun Yin, Yong Fang, et al.
Nature Medicine|January 13, 2026
Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trialTimothy A Yap, Randy F Sweis, Ulka Vaishampayan, et al.
Investigational New Drugs|November 3, 2021
Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single‑center, multi‑arm phase Ib studyKyaw Z Thein, Daniel D Karp, Apostolia Tsimberidou, et al.
Clinical Pharmacology and Therapeutics|August 21, 2025
Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor TuvusertibJatinder Kaur Mukker, Paul Matthias Diderichsen, Farina Hellmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2011
Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studiesTimothy A Yap, David Olmos, Andre T Brunetto, et al.
NPJ Precision Oncology|April 18, 2023
Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignanciesOmar Alhalabi, Roman Groisberg, Ralph Zinner, et al.
Pageof 26